← All trials
NCT00220987
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2005
- Primary completion
- Nov 30, 2008
- Completion date
- Nov 30, 2008
- First posted
- Sep 22, 2005
- Last posted
- Jan 29, 2009
- Enrollment
- 6104
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- University of MelbourneOverall official - principal investigator
- Australian and New Zealand Intensive Care Society Clinical Trials GroupCollaborator
- Canadian Critical Care Trials GroupCollaborator
- Health Research Council, New ZealandCollaborator
- National Health and Medical Research Council, AustraliaCollaborator
- University of SydneyOverall official - principal investigator
- University of SydneyStudy chair
- University of New South WalesOverall official - principal investigator
- University of New South WalesSponsor investigator
- University of OttawaOverall official - principal investigator
- University of British ColumbiaCollaborator
- University of British ColumbiaOverall official - principal investigator
- Australian National UniversityOfficial
- University of OttawaOfficial
- University of SydneyOfficial
- University of AucklandOfficial
- University of British ColumbiaOfficial
- University of New South WalesOfficial
- University of New South WalesOfficial
- University of MelbourneOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.